FORMULATION AND EVALUATION OF GLICLAZIDE CONTROLLED RELEASE TABLETS USING SODIUM ALGINATE, HPMC H4H IN DIFFERENT PROPORTIONS

Vinod Kumar K

doi:10.37022/jpmhs.v9i1.176

Authors

K. Vinod Kumar Professor, Department of Pharmaceutics, St.Ann’s college of Pharmacy, Chirala

DOI:

https://doi.org/10.37022/jpmhs.v9i1.176

Keywords:

Gliclazide, Type 2 Diabetes Mellitus, Sulfonylureas, Controlled Drug Release, Hydroxypropyl Methylcellulose (HPMC), ATP-sensitive Potassium Channels

Abstract

Gliclazide is a second-generation sulfonylurea widely used in the management of type 2 diabetes mellitus. It acts by stimulating insulin secretion from pancreatic β-cells through the closure of ATP-sensitive potassium channels, thereby improving glycemic control. In addition to its hypoglycemic effect, gliclazide exhibits beneficial antioxidant and hemovascular properties, which reduce oxidative stress and improve microcirculation. Compared to other sulfonylureas, gliclazide is associated with a lower risk of hypoglycemia and favorable cardiovascular safety. It shows good oral bioavailability and is commonly formulated as immediate-release and modified-release tablets to enhance patient compliance. Due to its efficacy, safety profile, and cost-effectiveness, gliclazide remains an important therapeutic option in the long-term treatment of type 2 diabetes mellitus. Gliclazide is commonly formulated as a modified-release dosage form to provide sustained glycemic control in patients with type 2 diabetes mellitus. Controlled-release formulations maintain steady plasma drug concentrations, thereby reducing fluctuations in blood glucose levels and minimizing the risk of hypoglycemia. The use of hydrophilic polymers such as HPMC and ethyl cellulose enhances drug release modulation and improves patient compliance by reducing dosing frequency. Controlled-release gliclazide tablets demonstrate improved therapeutic outcomes, better tolerability, and enhanced quality of life in diabetic patients. These formulations represent an effective approach for long-term diabetes management.

Downloads

Download data is not yet available.

References

AkanumaY , Kosaka K, Kanazawa Y, Kasuga M, Fukuda M, AokiS ,Long-term comparison of oral hypoglycemic agents in diabetic retinopathy. Gliclazide vs. other sulfonylureas , Institute for Diabetes Care and Research, Asahi Life Foundation ,2009, 5 (3) 228-235.

Baba S. Double-blind randomized control study with gliclazide Clin Eva 1983; 11(1):51-94.

Boulevard Armand , Frappier Laval, SERVIER CANADA Inc. 235,Quebec H7V 4A7 Date of Approval: December, 1989 Date of Revision: May 25, 2011 Control No. 145114

Campbell DB, Adriaenssens PI, Hopkins YW, Gordon B, Williams JRB: Pharmacokinetics and metabolism of gliclazide. A review Royal Soc Med Int Congr Symp 1980; 20:71-82.

Campbell DB, Forette B, Rolland A, Hopkins Y, Gordon BH: Gliclazide pharmacokinetics in the elderly Excerpta Medica 1982; 577:8.

Chan TK, Chan V, Teng CS, Yeung RTT: Effets du gliclazide et du glibenclamide sur les fonctionsplaquettaires, la fibrinolyse et I'équilibreglycémique chez des diabétiquesprésentantunerétinopathien Sem Hop Paris 1982; 58(19):1197-1200.

Chan TK, Ckan V, Teng CS, Yeung RTT: Progression of diabetic background retinopathy: the effect of gliclazide compared to glibenclamide and the relationship to haemobiological changes. Excerpta Medica 1982; 577:7.

Chiasson JL, Bergman RN, Verdy M, Hamet P, De Lean A: Study on effect of gliclazide on secretion and action of insulin in normal and type II diabetic humans Bull Int Diabete Fed 1987; 32(1):9-11.

Desnoyers P, Saint-Dizier D: The pharmacology of S 1702, a new highly effective oral antidiabetic drug with unusual properties ArzneimitteIforsch 1972; 22:1691-1695.

Duhault J, Lebon F: Protective activity of S 1702 on the microvascular system in normal and diabetic rats ArzneimitteIforsch 1972; 22:1686-1690.

Duhault J, Regnault F, Boulanger M, Tisserand F: Prevention of experimental obstructions in the retinal microcirculation Ophtalmologica 1975; 170:345-352.

Futijani B, Maeda J, Tsuboi T et coll: Effect of glicIazide on prostaglandin I2 formation in normaI streptozotocin-induced diabetic animals Jpn J Pharmacol 1983; 33:965-970.

Gamstedt A, Fagerberg SE: Long-term metabolic effects of gliclazide in NIDDM FADL Publish 1987; 16-19.

Golay A, Broquet C, Chabot V, Studer S, Felber JP: Effetsmétaboliques du gliclazide chez le diabétique de type II. Étude par calorimétrie indirect Schweiz Med Wochenschr 1984; 114(8):261-264.

Harrower A: Comparison of diabetic control in type 2 (non-insulin dependent) diabetic patients treated with different sulphonylureas. Curr Med Res Opin 1985; 9:676-680.